与慢性病患者抗凝血药物治疗的不同生存功能相关的因素
Diana Carolina Sandoval1,2, Paula Andrea Ruiz-Talero1,2, Sandra Brigitte Amado1,2
1Department of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia.
概括
在住院期间开始服用抗凝血药的慢性病患者面临高早期死亡率. 癌症,补贴医疗保健和静脉血栓塞栓症增加了这些患者的死亡风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 抗凝治疗对于治疗慢性病 (CKD) 患者的血栓事件至关重要.
- 然而,CKD患者经常有复杂的并发症和药物代谢变化,可能会影响抗凝剂的安全性和有效性.
- 了解这一群体的生存结果和相关因素对于优化临床管理至关重要.
研究的目的:
- 分析在住院期间开始抗凝治疗的慢性病患者的180天生存率.
- 为了确定与这种高风险队列的生存差异相关的因素.
主要方法:
- 对224名接受抗凝药治疗的CKD患者队列进行了回顾性生存分析.
- 卡普兰-梅尔曲线被用来估计生存率.
- 考克斯回归分析确定了死亡率的独立预测因素.
主要成果:
- 总体而言,180天死亡率为40.63%.
- 在心房 (AF) 与静脉血栓塞栓症 (VTE) 患者和不同CKD阶段 (3a与4,5与4) 的患者中观察到更高的存活率.
- 死亡的独立风险因素包括癌症 (HR 1.77),补贴医疗保健 (HR 1.47) 和静脉瘤 (HR 1.87). 动脉高血压和抗血小板单一治疗并没有显著影响生存率.
结论:
- 慢性病患者在住院期间启动抗凝药,表现出相当大的早期死亡率.
- 癌症,补贴医疗保健和静脉血栓塞栓症是死亡率的重要独立风险因素.
- 这些发现强调了需要加强对抗凝血剂的高风险CKD患者的监测和个性化治疗策略.
相关概念视频
01:17Factors Affecting Renal Clearance: Renal Impairment
402
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
402
01:11Renal Failure: Dose Adjustments
407
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
407
01:09Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
485
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
485
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
221
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
221
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
196
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
196
01:29Acute Kidney Injury III: Clinical Manifestations
778
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
778